Investors

Investing in positive change for patients and society.

INVESTING FOR GROWTH

We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.

Author Image

Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.

David Loew

CEO

IPSEN IN BRIEF

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Media Image

Strong results backed by innovation

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience. We delivered strong results in 2022. With a geographically balanced model, we delivered growth across total sales and core operating income.

PIPELINE

Innovating for a healthy tomorrow. Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.

Media Image

Shareholder information

We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.

Media Image

Regulated information

Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.

FIVE-YEAR STOCK INFORMATION

Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.

Your dedicated contacts